Abnova provides germline genetic DNA services to interested individuals, requesting physicians, clinics, and hospitals. These inherited genes are passed on from parents to offspring and play an important role in cancer risk and susceptibility. Moreover, knowledge of these heritable genes can be used not only to reduce the likelihood of developing cancer but also to select effective, evidenced-based therapy to treat cancer. The advent of next-generation sequencing (NGS) platforms has ushered a paradigm shift in the efficient, high-throughput identification and analysis of heritable predisposing genes and their variants across the human genome. Abnova leverages multiple NGS platforms to access these essential yet complex genetic changes to provide critical information for personalized and hereditary cancer management.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
An interpretative report of the germline cancer gene mutations will be provided. | |
|
|
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
BRCA2 Prostate Cancer Germline Sample Report | ||||||||||||||||||||||||
ATM Prostate Cancer Germline Sample Report | ||||||||||||||||||||||||
- Global : OEM@abnova.com / Japan : jutaku@funakoshi.co.jp
- TW : +886-2-8751-1888 / USA : +1(857) 639 0367 / Korea : +82-1670-5911.